Literature DB >> 20734416

The H63D HFE gene variant promotes activation of the intrinsic apoptotic pathway via mitochondria dysfunction following β-amyloid peptide exposure.

Nootchanat Mairuae1, Eric C Hall Ii, Poonlarp Cheepsunthorn, Sang Y Lee, James R Connor.   

Abstract

Numerous epidemiological studies suggest that the expression of the HFE allelic variant H63D may be a risk factor or genetic modifier for Alzheimer's disease (AD). The H63D variant alters cellular iron homeostasis and increases baseline oxidative stress. The elevated cellular stress milieu, we have proposed, may alter cellular responses to genetic and environmental determinants of AD. Accumulation of β-amyloid peptides (Aβ) is one of the most prominent pathogenic characteristics of AD. Several studies have demonstrated that Aβ can induce neuronal cell death through apoptosis. In this study, we provide evidence that an Aβ(25-35) fragment, which contains the cytotoxic sequence of the amyloid peptide, activates the intrinsic apoptotic pathway in SH-SY5Y human neuroblastoma cells expressing the HFE allelic variant H63D to a greater extent than in cells with wild-type (WT) HFE. Specifically, Aβ(25-35) peptide exposure significantly induced Bax translocation from the cytosol to the mitochondria in H63D-expressing cells compared with WT cells. This translocation was associated with increased cytochrome c release from mitochondria and an increase in active caspase-9 and caspase-3 activity in H63D cells. Consequently, there is increased apoptosis in cells expressing the H63D variant as opposed to cells expressing WT HFE. We also found increased amyloid precursor protein (APP) and Aβ(1-42) peptide in the mitochondrial compartment as well as increased mitochondrial stress in H63D-expressing cells compared with WT. These findings support our hypothesis that the presence of the HFE H63D allele enables factors that trigger neurodegenerative processes associated with AD and predisposes cells to cytotoxcity.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20734416     DOI: 10.1002/jnr.22466

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  7 in total

1.  HFE genetic variability and risk of alcoholic liver disease: A meta-analysis.

Authors:  Yan-Yan Xu; Yu-Han Tang; Xiao-Ping Guo; Jing Wang; Ping Yao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

Review 2.  The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin.

Authors:  Douglas G Peters; James R Connor; Mark D Meadowcroft
Journal:  Neurobiol Dis       Date:  2015-08-22       Impact factor: 5.996

3.  Statins accelerate disease progression and shorten survival in SOD1(G93A) mice.

Authors:  Xiaowei W Su; Wint Nandar; Elizabeth B Neely; Zachary Simmons; James R Connor
Journal:  Muscle Nerve       Date:  2016-05-19       Impact factor: 3.217

4.  Hemochromatosis (HFE) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy.

Authors:  Asha R Kallianpur; Mariana Gerschenson; Todd Hulgan; Harpreet Kaur; David B Clifford; David W Haas; Deborah G Murdock; Justin C McArthur; David C Samuels; David M Simpson
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-22       Impact factor: 2.205

5.  Age-Dependent Behavioral and Metabolic Assessment of App NL-G-F/NL-G-F Knock-in (KI) Mice.

Authors:  Shanshan Wang; Taiga Ichinomiya; Paul Savchenko; Swetha Devulapalli; Dongsheng Wang; Gianna Beltz; Takashi Saito; Takaomi C Saido; Steve L Wagner; Hemal H Patel; Brian P Head
Journal:  Front Mol Neurosci       Date:  2022-07-29       Impact factor: 6.261

Review 6.  HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease.

Authors:  Fatima Ali-Rahmani; Cara-Lynne Schengrund; James R Connor
Journal:  Front Pharmacol       Date:  2014-07-08       Impact factor: 5.810

7.  Haplotype analysis of the HFE gene among populations of Northern Eurasia, in patients with metabolic disorders or stomach cancer, and in long-lived people.

Authors:  S V Mikhailova; V N Babenko; D E Ivanoshchuk; M A Gubina; V N Maksimov; I G Solovjova; M I Voevoda
Journal:  BMC Genet       Date:  2016-06-17       Impact factor: 2.797

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.